Tirzepatide

At a glance

What is tirzepatide?

Tirzepatide is a synthetic peptide -- a 39-amino-acid chain -- that simultaneously activates two receptors for gut hormones: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1).^[9] This dual-receptor approach earned it the nickname "twincretin."

The compound was developed by Eli Lilly and Company, with core patents filed in 2016. It received its first FDA approval in May 2022 as Mounjaro for type 2 diabetes, followed by approval as Zepbound for chronic weight management in November 2023, and for obstructive sleep apnea in December 2024.^[16][17]

Tirzepatide is built on the GIP amino acid backbone, but has been engineered to also activate the GLP-1 receptor. Several structural modifications make it long-acting: two non-coded amino acid residues (Aib at positions 2 and 13) protect it from enzymatic breakdown, and a C20 fatty diacid moiety attached to Lys20 enables it to bind to albumin in the bloodstream, extending its half-life to approximately 5 days and allowing once-weekly dosing.

Unlike many peptides covered on Peptide Garden, tirzepatide has gone through the full FDA approval process -- large-scale Phase III trials with thousands of participants, extensive safety monitoring, and post-marketing surveillance. The evidence base here is fundamentally different from that of research-stage peptides.

How it works

In plain terms, tirzepatide mimics two gut hormones that your body naturally releases after eating. These hormones -- GIP and GLP-1 -- help control blood sugar, reduce appetite, and regulate how your body stores energy. By activating both pathways at once, tirzepatide produces stronger effects on weight and blood sugar than drugs that target only one.^[10]

Think of it as working on two channels simultaneously: one primarily affecting insulin response and fat metabolism (GIP), and another primarily affecting appetite and glucose regulation (GLP-1). The combination produces more than the sum of its parts.

What the research says

Tirzepatide has one of the strongest evidence bases in modern pharmacology, with over 10,000 participants across Phase III programs, three FDA-approved indications, and head-to-head superiority over the leading comparator. The clinical data is world-class.

Research timeline

Tirzepatide has moved from first-in-human dosing to three FDA approvals in under a decade -- a remarkably fast trajectory reflecting the strength of the clinical data:

Human clinical trials

Tirzepatide has been studied in two major Phase III programs with a combined enrollment exceeding 10,000 participants:

SURPASS program (Type 2 Diabetes): Five core trials (SURPASS-1 through SURPASS-5) enrolling over 6,000 patients demonstrated superior glycemic control and weight loss across all comparators, including semaglutide 1 mg, insulin glargine, and insulin degludec.^[4][3]

SURMOUNT program (Obesity/Weight Management): Five core trials enrolling over 5,000 patients, including the landmark SURMOUNT-1 trial and the head-to-head SURMOUNT-5 comparison against semaglutide.^[1][2]

What the evidence shows

People come to tirzepatide primarily for weight loss and blood sugar control. Here's what the published research tells us about the most common areas of interest:

Safety & side effects

What clinical trials show

Tirzepatide's safety profile is well-characterized from Phase III programs with over 10,000 participants and extensive post-marketing surveillance.^[13]

Gastrointestinal events (the most common side effects): These are dose-dependent and typically most pronounced during dose escalation:

• Nausea: ~20% (vs. ~10% comparators)
• Diarrhea: ~16% (vs. ~9% comparators)
• Vomiting: ~9% (vs. ~5% comparators)
• Constipation: ~7%
• Decreased appetite (common, dose-dependent)
• Dyspepsia/abdominal pain (common)

GI side effects occurred in 39% (5 mg), 46% (10 mg), and 49% (15 mg) of patients. Most were mild-to-moderate, transient, and occurred during dose escalation periods. The slow dose-titration schedule (4 weeks per increment) is specifically designed to minimize these effects.

Beyond the common, transient events above, the FDA label also lists less common postmarketing GI adverse reactions: ileus, intestinal obstruction, and severe constipation including fecal impaction. These are uncommon but worth knowing about, particularly if severe abdominal symptoms develop.^[21]

Serious safety concerns

• Pancreatitis: Acute pancreatitis has been reported. Contraindicated in patients with a history of pancreatitis.
• Cholecystitis/gallstones: Incidence up to 0.6% in trials. Risk appears related to rapid weight loss.
• Acute kidney injury: Reported, likely related to dehydration from GI events. Use caution in patients with renal impairment.
• Pulmonary aspiration during anesthesia: Because tirzepatide delays gastric emptying, the FDA label carries a Warnings & Precautions note on pulmonary aspiration during general anesthesia or deep sedation -- there have been rare reports of retained gastric contents despite recommended preoperative fasting. Tell your care team you are taking tirzepatide before any surgery or procedure. (Note: the specific perioperative guidance to "hold the drug" before surgery comes from anesthesiology societies, not the FDA label itself.)^[21]
• Lean mass loss: Approximately 25% of total weight lost is lean mass (the remaining 75% is fat mass). This ratio is consistent across dose groups and comparable to other weight-loss interventions.^[14] A 2026 European consensus statement (EASO, EFAD and ECPO) sets out practical nutrition, physical-function and psychological guidance for adults on incretin therapy — currently the best guideline-grade anchor for managing muscle and micronutrient concerns.^[31]
• Weight regain on discontinuation: SURMOUNT-4 demonstrated that most patients who stop tirzepatide regain a substantial portion of lost weight within one year.^[6]

Emerging safety signals

Treatment discontinuation

Approximately 10% of participants at the 15 mg dose discontinued treatment due to adverse events in clinical trials (vs. 4% for placebo). Most discontinuations were due to GI side effects during dose escalation.

FDA-approved dosing

Tirzepatide is available as a pre-filled pen injector (KwikPen) for once-weekly subcutaneous injection. The following dosing schedule is from the FDA-approved prescribing information for both Mounjaro and Zepbound:

• Maintenance doses: 5 mg, 10 mg, or 15 mg weekly
• Maximum dose: 15 mg subcutaneously once weekly
• Administration: Subcutaneous injection in abdomen, thigh, or upper arm
• Dose increases: In 2.5 mg increments after a minimum of 4 weeks at each dose level. Slow escalation reduces GI side effects.
• No oral formulation is currently available (unlike semaglutide)

Legal & regulatory status

As of August 2026:

FDA status

Tirzepatide is FDA-approved for three indications:

• Mounjaro (May 2022): Type 2 diabetes mellitus
• Zepbound (November 2023): Chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity
• Zepbound (December 2024): Moderate-to-severe obstructive sleep apnea in adults with obesity

It is available only with a prescription. A monthly pre-filled pen (KwikPen) option has been approved by the FDA.^[16][17]

Nothing changed between late June and mid-August 2026. No new approvals, no new indications, and no approved label supplements for tirzepatide in that window. In particular, the strong observational cardiovascular result published in August 2026 is not a regulatory event — tirzepatide still carries no FDA cardiovascular indication.

The compounding story

This is one of the most significant regulatory developments of 2024-2025 and directly affects patient access:

• When Eli Lilly could not meet demand, tirzepatide was placed on the FDA drug shortage list, which temporarily permitted compounding pharmacies to produce it.
• In October 2024, the FDA removed tirzepatide from the shortage list, beginning the process of ending compounding.
• February 18, 2025: Compounding discretion ended for Section 503A pharmacies (state-licensed).
• March 19, 2025: Compounding discretion ended for Section 503B outsourcing facilities.
• May 2025: US District Court upheld FDA's shortage resolution decision.

That is the rule. The market is another matter. A July 2026 secret-shopper study in JAMA Health Forum contacted weight-loss clinics and medical spas in West Virginia and Oklahoma and found 75 businesses still selling compounded GLP-1 medications more than a year after the shortages ended — including oral formulations and products mixed with B vitamins, neither of which matches any FDA-approved product. Among the supplying compounding facilities the researchers could verify, 4 of 21 (19.0%) were not licensed to perform sterile compounding at all. Two caveats: the data were collected in late 2025, and two states are not a national picture. But if you are being offered compounded tirzepatide, the licensure question is a fair and specific one to ask.^[30]

Pricing

• Mounjaro (list price): ~$1,080/month (any dose strength)
• Zepbound (list price): ~$1,086/month
• LillyDirect (Zepbound vial, self-pay): $499/month (with timely refill)
• With Eli Lilly Savings Card: Copay as low as $25/month for commercially insured patients
• Medicare: A temporary CMS demonstration, the GLP-1 Bridge, began July 1, 2026 and offers eligible Part D and MA-PD enrollees roughly $50 per 30-day supply of Zepbound KwikPen for weight management. It sits outside the standard Part D benefit, so copays do not count toward the deductible or the out-of-pocket cap. Published accounts of the end date and covered-drug list disagree — check CMS directly rather than a summary

WADA / USADA status

Tirzepatide is not prohibited by WADA. It is currently on the WADA Monitoring Program (2026) alongside semaglutide, meaning its use by athletes is being tracked but does not constitute a violation. It could potentially move to the prohibited list in future updates. A decision on whether to prohibit GLP-1-based drugs is expected by the end of 2026 or in 2027, potentially ahead of the LA 2028 Olympics.

How tirzepatide compares to semaglutide

Semaglutide is the natural comparator -- both are injectable GLP-1 pathway drugs used for weight management and diabetes. Here's how they stack up based on head-to-head and cross-trial data:

The key tradeoffs:

• Weight loss: Tirzepatide wins. SURMOUNT-5 head-to-head: 20.2% vs. 13.7% at 72 weeks.^[2]
• Glycemic control: Tirzepatide wins. SURPASS-2: HbA1c reduction of 2.46% vs. 1.86%.^[3]
• Cardiovascular protection: Semaglutide retains the edge in randomized evidence. The SELECT trial (n=17,604) demonstrated a 20% reduction in MACE events versus placebo. Tirzepatide's dedicated SURPASS-CVOT trial (n=13,299) met noninferiority to dulaglutide (an established GLP-1 RA) for 3-point MACE but did not show superiority -- a different, weaker bar than SELECT's placebo-controlled event reduction.^[18] That comparison changed in August 2026, though not in the trial column: a BMJ target trial emulation of 52,971 adults with type 2 diabetes and established atherosclerotic disease compared tirzepatide against sitagliptin -- a cardiovascularly neutral placebo proxy -- and found 1-year MACE risk of 2.9% vs. 4.4% (HR 0.68, 95% CI 0.58-0.80, number needed to treat 70), with all-cause mortality also lower (HR 0.55). It is observational claims data, so it cannot carry the weight of a randomized placebo-controlled trial, and it does not create an FDA indication. But it does answer the question SURPASS-CVOT's design left open, and it points the same direction.^[24] A separate trial, SUMMIT, found tirzepatide cut cardiovascular death or worsening heart failure by 38% in people with HFpEF and obesity,^[19] but Lilly withdrew its U.S. heart-failure application in 2025 after the FDA required a confirmatory trial, so tirzepatide carries no heart-failure indication.^[20] A June 2026 JACC post hoc analysis of SURMOUNT-1 found tirzepatide broadly improved cardiovascular risk biomarkers, including inflammation (hsCRP).^[23]
• Oral option: Semaglutide has an oral formulation (Rybelsus/oral Wegovy). Tirzepatide is injection-only.
• Compounding access: Semaglutide has maintained some compounding flexibility. Tirzepatide compounding is no longer permitted.
• Cost: Comparable at list price (~$1,000-1,100/month).

Neither drug is universally superior. The choice between them depends on clinical priorities: maximum weight loss and glycemic control favor tirzepatide; randomized, placebo-controlled cardiovascular evidence and oral dosing favor semaglutide.